Clinical trial
Xolair in Patients With Chronic Sinusitis
NCT00117611 · University of Chicago, Other · Completed
Key facts
| NCT number | NCT00117611 |
|---|---|
| Title | Xolair in Patients With Chronic Sinusitis |
| Official title | Effects of Anti-IgE Antibody Omalizumab (Xolair) on Patients With Chronic Sinusitis and a Positive Allergen Test |
| Lead sponsor | University of Chicago, Other |
| Collaborators | Genentech, Inc. Industry Novartis Pharmaceuticals |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Sinusitis |
| Intervention type | Drug |
| Interventions | Anti-IgE antibody omalizumab or placebo |
| Enrollment | 14 |
| Start date | Jul 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | Jan 1, 2009 |
| First posted | Jul 7, 2005 |
| Last update posted | Sep 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: